Literature DB >> 15492948

Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy.

Robyn G Langham1, Darren J Kelly, Renae M Gow, Yuan Zhang, John K Dowling, Napier M Thomson, Richard E Gilbert.   

Abstract

BACKGROUND: Urotensin II (UII) is an 11-amino acid vasoactive peptide, recently identified as the ligand for a novel G protein-coupled receptor, GPR-14 (renamed urotensin receptor [UT]). In addition to its potent vasoconstrictive actions, UII also has trophic and profibrotic effects, leading to its implication in the pathogenesis of heart failure. However, elevated plasma UII levels also were reported in association with renal impairment and diabetes. Accordingly, the present study sought to examine the expression and localization of UII and its receptor in kidney tissue from patients with diabetic nephropathy.
METHODS: We quantified UII and UT gene expression in renal biopsy tissue samples from patients with diabetic nephropathy by using quantitative real-time polymerase chain reaction and determined the intrarenal distribution of their peptides by means of immunohistochemistry.
RESULTS: In human diabetic tissue, gene expression of UII and UT were increased 45- and almost 2,000-fold in comparison to control nephrectomy tissue, respectively (P < 0.0001). Immunohistochemical studies showed intense UII peptide staining in diabetic tissue localized predominantly to tubular epithelial cells, and fluorescein-labeled ligand binding studies showed a similar tubular pattern of distribution.
CONCLUSION: In the context of its known biological actions, the dramatic overexpression of UII and its receptor implicate this vasoactive peptide as a possible novel factor in the pathogenesis of diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15492948

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  20 in total

1.  Renal impairment, hypertension and plasma urotensin II.

Authors:  Ari Mosenkis; Radhakrishna R Kallem; Theodore M Danoff; Nambi Aiyar; Jonathan Bazeley; Raymond R Townsend
Journal:  Nephrol Dial Transplant       Date:  2010-07-09       Impact factor: 5.992

2.  Urotensin-II induces ear flushing in rats.

Authors:  J-s Qi; R Schulingkamp; T J Parry; R Colburn; D Stone; B Haertlein; L K Minor; P Andrade-Gordon; B P Damiano
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

Review 3.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

4.  Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.

Authors:  Stephen A Douglas; David J Behm; Nambi V Aiyar; Diane Naselsky; Jyoti Disa; David P Brooks; Eliot H Ohlstein; John G Gleason; Henry M Sarau; James J Foley; Peter T Buckley; Dulcie B Schmidt; William E Wixted; Katherine Widdowson; Graham Riley; Jian Jin; Timothy F Gallagher; Stanley J Schmidt; Lance Ridgers; Lisa T Christmann; Richard M Keenan; Steven D Knight; Dashyant Dhanak
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

5.  The network map of urotensin-II mediated signaling pathway in physiological and pathological conditions.

Authors:  D A B Rex; G P Suchitha; Akhina Palollathil; Anagha Kanichery; T S Keshava Prasad; Shobha Dagamajalu
Journal:  J Cell Commun Signal       Date:  2022-02-16       Impact factor: 5.782

6.  Loss of urotensin II receptor diminishes hyperglycemia and kidney injury in streptozotocin-treated mice.

Authors:  Dieniffer Peixoto-Neves; Praghalathan Kanthakumar; Ravi Kumar; Hitesh Soni; Adebowale Adebiyi
Journal:  J Mol Endocrinol       Date:  2022-03-25       Impact factor: 4.869

7.  Can early myocardial infarction-related deaths be diagnosed using postmortem urotensin receptor expression levels?

Authors:  Mustafa Talip Sener; Emre Karakus; Zekai Halici; Erol Akpinar; Atilla Topcu; Ahmet Nezih Kok
Journal:  Forensic Sci Med Pathol       Date:  2014-06-18       Impact factor: 2.007

8.  Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus.

Authors:  Patricia N Sidharta; Klaus Rave; Lutz Heinemann; Eleonora Chiossi; Stephan Krähenbühl; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

9.  Potential Clinical Implications of the Urotensin II Receptor Antagonists.

Authors:  Philip Tsoukas; Emilie Kane; Adel Giaid
Journal:  Front Pharmacol       Date:  2011-07-22       Impact factor: 5.810

Review 10.  Therapeutic potential of blockade of the urotensin II system in systemic hypertension.

Authors:  Henry Krum; Will Kemp
Journal:  Curr Hypertens Rep       Date:  2007-03       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.